LLS\ IFLI Research Accelerator for Follicular Lymphoma I (RAFL-I)

LLS and IFLI are jointly funding creative and ambitious research and development proposals under the RAFL program. The grant program for RAFL-I will support two programs: A Synergistic Team Award (STA) and a Translational Grant (TRL) Award.

Synergistic Team Awards (STA) will support a coordinated, focused and significant effort to understand central disease mechanisms and develop effective novel therapies in treating FL.

Key features of the STA grant include:

• Research program led by a single program director (PD).
• Research program must consist of 2-4 distinct but synergistic projects, each with a Project Lead.
• One of the Project Leads may be the PD. Project Leads may be at the same or different institutions.
• A demonstration of prior collaboration is desirable.
• $6.5 M total award; $1.3M/yr for up to 5 years of funding.
• Annual site visit by LLS-IFLI required for the next year of funding.
• A single STA will be awarded in RAFL-I.

Translational Awards (TRL) will support translational research that moves potential therapeutic candidates toward clinical trials within 2-3 years.

Key features of the TRL awards include:

• A clearly outlined translational aspect toward clinical trials is the focus, but outstanding biological research proposals without an immediate translational element will be considered.
• Project led by a single PI, but may have a Co-PI, if appropriate.
• Substantial preliminary data are expected.
• Up to $1.75M total award; $350,000/yr for up to 5 years of funding.
• Major Go/No Go decision will occur after 2 years.
• Indirect costs capped at 10% of total award amount.
• Up to 2 Translational Grants (TRLs) will be awarded in RAFL-I.

Research Authority due date: 2.9.24

LOI  (required) due date: 9.9.24

Full proposal due date: 13.1.25